A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro

Drug Metabolism and Disposition

Volumn 29, Issue 3, 2001, Pages 282-288

  Ishigami, M ^a   Honda, T ^a   Takasaki, W ^a   Ikeda, T ^a   Komai, T ^a   Ito, K ^a   Sugiyama, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE; MEVINOLIN; MEXAZOLAM; PRAVASTATIN; PRODRUG; SIMVASTATIN;

ARTICLE; DRUG EFFECT; DRUG OXIDATION; ENZYME INHIBITION; ENZYME METABOLISM; FEMALE; HUMAN; IN VITRO STUDY; LIVER MICROSOME; MALE; PARTITION COEFFICIENT; PRIORITY JOURNAL;

ACIDS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE SERA; KINETICS; LACTONES; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PRAVASTATIN; SOLUBILITY;

EID: 0035111913     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved
2. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
3. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions
4. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
5. Effect of itraconazole on pharmacokinetics of atorvastatin
6. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
7. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
8. Section I Physical chemical properties. TG No. 107, Partition coefficient (n·Octanol/Water)
9. Mexazolam metabolism by eDNA expressed human cytochrome P450 forms using a recombinant vaccinia vires
10. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s
11. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
12. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin
13. Cooperativity in oxidations catalyzed by cytochrome P450 3A4
14. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
15. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG·CoA reductase
16. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes
17. Physicochemical properties of pravastatin, lovastatin, mevastatin and simvastatin